TCR2 Therapeutics (TCRR) PT Lowered to $4 at Wedbush

May 12, 2022 1:27 PM EDT Send to a Friend

Wedbush analyst David Nierengarten lowered ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

TCR2 Therapeutics (TCRR) PT Lowered to $4 at Wedbush

Member Login

Free News Feed